Antihypertensive prescribing patterns in non-dialysis dependent chronic kidney disease: Findings from the Salford Kidney Study

Table 2 Number of patients prescribed each antihypertensive class at baseline, organized by estimated glomerular filtration rate categories at baseline

Antihypertensive class	eGFR>60, n = 2181	eGFR 45-59, n = 4911	eGFR 30-45, n = 9621	eGFR 15-29, n = 11741	eGFR < 15, n = 3851	Total, n = 32301	P value1
None	54 (24.8)	73 (14.9)	97 (10.1)	78 (6.6)	26 (6.8)	328 (10.2)	< 0.001
Three or more agents	57 (26.1)	158 (32.2)	397 (41.3)	565 (48.1)	206 (53.5)	1383 (42.8)	< 0.001
Diuretic (thiazide and loop)	58 (26.6)	172 (35.0)	441 (45.8)	641 (54.6)	213 (55.3)	1525 (47.2)	< 0.001
CCB (dihydropyridine)	58 (26.6)	149 (30.3)	364 (37.8)	480 (40.9)	205 (53.2)	1256 (38.9)	< 0.001
CCB (non- dihydropyridine)	6 (2.8)	11 (2.2)	44 (4.6)	50 (4.3)	23 (6.0)	134 (4.1)	0.055
Beta-blocker	51 (23.4)	133 (27.1)	324 (33.7)	443 (37.7)	156 (40.5)	1107 (34.3)	< 0.001
Alpha-blocker	28 (12.8)	72 (14.7)	186 (19.3)	335 (28.5)	158 (41.0)	779 (24.1)	< 0.001
Central agents	9 (4.1)	15 (3.1)	34 (3.5)	59 (5.0)	33 (8.6)	150 (4.6)	0.001
Vasodilators	2 (0.9)	2 (0.4)	6 (0.6)	13 (1.1)	7 (1.8)	30 (0.9)	0.189
RAS blocker	126 (57.8)	316 (64.4)	616 (64.0)	733 (62.4)	192 (50.0)	1983 (61.4)	< 0.001
Dual RAS blockers	22 (10.1)	34 (7.0)	50 (5.2)	67 (5.7)	14 (31.6)	187 (5.8)	0.014
Spironolactone/eplerenone	7 (3.2)	17 (3.5)	36 (3.7)	44 (3.7)	8 (2.1)	112 (3.5)	0.599

¹Absolute number for frequencies (percentage). The P values were calculated by the χ² test.

CCB: Calcium channel blocker; eGFR: estimated glomerular filtration rate expressed as mL/min/1.73 m²; RAS: Renin angiotensin system.